This website is intended for healthcare professionals only
User log in




Trial log in
  

Renal considerations in patients with type 2 diabetes


This promotional module has been initiated, funded and reviewed by Boehringer Ingelheim. The content of this industry-supported learning activity has been generated by Practice Nurse.

INTRODUCTION

Renal impairment frequently co-exists with diabetes.1 As many agents used to control blood glucose are metabolised by the kidneys, reduced renal function has important implications for the choice and dose of oral hypoglycaemic agents.

This module aims to raise awareness of how chronic kidney disease impacts on the management of hyperglycaemia, including the need for dose reduction for many agents used in the management of type 2 diabetes.

LEARNING OBJECTIVES

On completion of this module, the general practice nurse should:

  • Be familiar with the risk of declining renal function over time in patients with type 2 diabetes
  • Be able to identify the factors that lead to the development of diabetic kidney disease
  • Understand how to diagnose renal impairment and stage CKD
  • Be aware of how CKD impacts on the management of hyperglycaemia, including the need for dose reduction for many agents used in the management of type 2 diabetes

This module is one of a series of five. Others in the series are:

This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned.

Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log.


References

1. NICE CG182. Chronic kidney disease in adults: assessment and management, 2014 (updated 2015). https://www.nice.org.uk/Guidance/cg182 [Accessed March 2021] 

Job Code: PC-GB-103940

Date of preparation: March 2021


You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events.

Click here for Trajenta (linagliptin) Prescribing Information

Click here for Jardiance (empagliflozin) Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

START MODULE